Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Spain
  4. Bolsas y Mercados Espanoles
  5. Almirall, S.A.
  6. Summary
    ALM   ES0157097017

ALMIRALL, S.A.

(ALM)
  Report
Real-time Estimate Tradegate  -  12:18 2022-11-30 pm EST
9.230 EUR   +0.87%
04:27aAlmirall S A : appoints Mercedes Diz as VP, Corporate Strategy
PU
11/28Almirall joins FACILITATE, a patient-driven Innovative Medicines Initiative (IMI) project to enable the use of clinical trial data by study participants
BU
11/18Spain's Almirall Enters Licensing Deal For Nausea, Vomiting Drug With Italian Drugmaker Teofarma
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Days
:
Hours
:
Minutes
:
Seconds
Quotes 5-day view   Delayed Quote. Delayed Bolsas Y Mercados Espanol…
11/24/2022 11/25/2022 11/28/2022 11/29/2022 11/30/2022 Date
8.965(c) 8.945(c) 8.995(c) 9.15(c) 9.255 Last
394 736 174 501 145 448 339 003 220 256 Volume
+0.34% -0.22% +0.56% +1.72% +1.15% Change
More quotes
Estimated financial data (e)
Sales 2022 859 M 888 M 888 M
Net income 2022 30,5 M 31,5 M 31,5 M
Net Debt 2022 167 M 173 M 173 M
P/E ratio 2022 42,1x
Yield 2022 1,70%
Sales 2023 906 M 936 M 936 M
Net income 2023 44,5 M 46,0 M 46,0 M
Net Debt 2023 119 M 123 M 123 M
P/E ratio 2023 35,2x
Yield 2023 1,87%
Capitalization 1 661 M 1 717 M 1 717 M
EV / Sales 2022 2,13x
EV / Sales 2023 1,97x
Nbr of Employees 1 786
Free-Float 40,3%
More Financials
Company
Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The Company's activities are divided into four business segments: Own network,... 
Sector
Pharmaceuticals
Calendar
02/20Earnings Release
More about the company
Ratings of Almirall, S.A.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about ALMIRALL, S.A.
04:27aAlmirall S A : appoints Mercedes Diz as VP, Corporate Strategy
PU
11/28Almirall joins FACILITATE, a patient-driven Innovative Medicines Initiative (IMI) proje..
BU
11/18Spain's Almirall Enters Licensing Deal For Nausea, Vomiting Drug With Italian Drugmaker..
MT
11/10Transcript : Almirall, S.A., Q3 2022 Earnings Call, Nov 10, 2022
CI
11/10Spain's Almirall Q3 core earnings fall 13%; keeps outlook
RE
11/10Almirall's Nine-month 2022 Results
BU
11/10Almirall, S.A. Maintains Earnings Guidance for the Full Year of 2022
CI
11/10Almirall, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
11/08Almirall S.A. Opens a New Subsidiary for the Czech Republic and Slovakia
CI
11/03Almirall S A : Chairman, Carlos Gallardo, appointed as Interim CEO
PU
10/28Almirall S A : Shedding Light on Psoriasis campaign exposes the impact of this disease on ..
PU
10/28Almirall Files Marketing Application In Europe For Atopic Dermatitis Medication
MT
10/28Almirall, S.A. Announces EMA Acceptance for Filing of Marketing Authorization Applicati..
CI
10/21Almirall PROSES study demonstrates appropriate acne treatment decreases the burden of i..
BU
10/13Almirall S A : partners with the Chemical Institute of Sarrià (IQS) to bring pharmacy stud..
PU
More news
News in other languages on ALMIRALL, S.A.
11/18L'espagnol Almirall conclut un accord de licence pour un médicament contre les nausées ..
11/10Almirall mantiene sus previsiones tras descenso del ebitda en las cifras a septiembre
11/10Le bénéfice principal du troisième trimestre de l'espagnol Almirall chute de 13 %, mais..
11/10Bolsa de Madrid: ┐Feliz cumpleaños, bitcoin?
11/10Almirall, S.A. maintient ses prévisions de bénéfices pour l'ensemble de l'année 2022
More news
Analyst Recommendations on ALMIRALL, S.A.
More recommendations
ETFs positioned on ALMIRALL, S.A.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
UBS ETF - MSCI EMU Small Cap A-dis - EUR0.17%-0.39%Europe
Lyxor MSCI EMU Small Cap (DR) - Dist - EUR0.16%-0.12%Europe
IShares MSCI Europe Small-Cap ETF - USD0.07%0.20%Europe
Invesco FTSE RAFI Developed Markets ex-U.S....0.04%1.65%World
Vanguard FTSE All-World ex-US Small-Cap ETF - USD0.04%0.50%World
More ETFs positioned on ALMIRALL, S.A.
Chart ALMIRALL, S.A.
Duration : Period :
Almirall, S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALMIRALL, S.A.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Last Close Price 9,15 €
Average target price 12,86 €
Spread / Average Target 40,5%
EPS Revisions
Managers and Directors
Carlos Gallardo PiquÚ Chairman & Chief Executive Officer
Michael McClellan Chief Financial Officer
Volker Koscielny Chief Medical Officer
Karl Ziegelbauer Chief Scientific Officer
Eloi Crespo Cervera Senior Vice President-Industrial Operations
Sector and Competitors
1st jan.Capi. (M$)
ALMIRALL, S.A.-19.03%1 717
JOHNSON & JOHNSON2.93%460 384
ELI LILLY AND COMPANY32.42%345 817
ABBVIE INC.16.84%279 679
PFIZER, INC.-16.19%277 803
NOVO NORDISK A/S19.71%276 497